Follow-On Biologics Process May Allow Post-Approval Immunogenicity Tests

A regulatory process for follow-on biologics could allow for post-approval immunogenicity testing, FDA Office of Biotechnology Products Principal Advisor for Regulatory Science & Review Anthony Mire-Sluis, PhD, suggested